Healthcare -
Biotechnology - NASDAQ - US
$ 4.93
-5.01 %
$ 271 M
Market Cap
-1.47
P/E
1. INTRINSIC VALUE
Balance Sheet
Verastem, Inc.
| Current Assets | 95 M |
| Cash & Short-Term Investments | 88.8 M |
| Receivables | 200 K |
| Other Current Assets | 5.94 M |
| Non-Current Assets | 6.58 M |
| Long-Term Investments | 0 |
| PP&E | 1.44 M |
| Other Non-Current Assets | 5.14 M |
| Current Liabilities | 31 M |
| Accounts Payable | 4.03 M |
| Short-Term Debt | 1.99 M |
| Other Current Liabilities | 25 M |
| Non-Current Liabilities | 99.5 M |
| Long-Term Debt | 41.3 M |
| Other Non-Current Liabilities | 58.2 M |
EFFICIENCY
Earnings Waterfall
Verastem, Inc.
| Revenue | 10 M |
| Cost Of Revenue | 26 K |
| Gross Profit | 9.97 M |
| Operating Expenses | 125 M |
| Operating Income | -115 M |
| Other Expenses | 15.7 M |
| Net Income | -131 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Verastem, Inc.
| Net Income | -131 M |
| Depreciation & Amortization | 26 K |
| Capital Expenditures | -28 K |
| Stock-Based Compensation | 7.34 M |
| Change in Working Capital | 3.72 M |
| Others | 21.7 M |
| Free Cash Flow | -105 M |
Wall Street Analysts Price Targets
Verastem, Inc.
Wall Street analysts predict an average 1-year price target for VSTM of $10.3 , with forecasts ranging from
a
low of
$7 to a high of $14 .
VSTM Lowest Price Target
Wall Street Target
7 USD
41.99%
VSTM Average Price Target
Wall Street Target
10.3 USD
109.60%
VSTM Highest Price Target
Wall Street Target
14 USD
183.98%
4. DIVIDEND
ANALYSIS
VSTM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Verastem, Inc.
Sold
0-3 MONTHS
574 K USD 2
3-6 MONTHS
61.3 K USD 4
6-9 MONTHS
10.3 K USD 4
9-12 MONTHS
16.5 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall.
businesswire.com
- 2 weeks ago
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
zacks.com
- 3 weeks ago
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York. A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company's website at www.verastem.com. A.
businesswire.com
- 3 weeks ago
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-line for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). As of April 25, 2025, patients in the dose level 1.
businesswire.com
- 1 month ago
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. Tempus completed confirmatory testing in Verastem's Phase 2 RAMP-201 clinical trial, which evaluated the combinati.
businesswire.com
- 1 month ago
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the first quarter ended March 31, 2025. “In the first quarter of 2025, we continued to make progress with our pipeline programs by exercising our option early to license VS-7375 from our partner GenFleet Therapeutics, completing enrollment in the initial c.
businesswire.com
- 1 month ago
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #FDA--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK is the fi.
businesswire.com
- 1 month ago
U.S. FDA approves Verastem's cancer therapy
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.
reuters.com
- 1 month ago
Verastem Oncology to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May: H.C. Wainwright 3rd Annual BioConnect Investor Conference: Fireside chat on Tuesday, May 20 at 12:00 pm ET 2025 RBC Capital Markets Global Healthcare Conference: Fireside chat on Tuesday, May 20 at.
businesswire.com
- 1 month ago
Verastem Oncology Announces $75 million Private Placement
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of $7.00 per share and, in lieu of common stock to certain investors, $51 million of pre-funded warrants.
businesswire.com
- 1 month ago
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
zacks.com
- 2 months ago
Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination
Verastem, Inc.'s priority review PDUFA date of avutometinib + defactinib for treatment of patients with recurrent LGSOC is expected June 30th of 2025; At this time, no FDA advisory committee to be held. The global Non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; KRAS G12C variant is the most common KRAS mutation, accounting for 13% of NSCLC cases. Data from phase 1/2 RAMP-203 study, using avutometinib + LUMAKRAS with or without defacinib to treat patients with KRAS G12C mutant NSCLC, is expected to be presented 2nd half of 2025.
seekingalpha.com
- 2 months ago
8. Profile
Summary
Verastem, Inc. VSTM
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 271 M
Dividend Yield
0.00%
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Contact
117 Kendrick Street, Needham, MA, 02494
https://www.verastem.com
IPO
Date
Jan. 27, 2012
Employees
78
Officers
Ms. Cathy Carew
Chief Organizational Effectiveness Officer
Ms. Colleen Mockbee
Global Head of Regulatory Affairs & Development
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Mr. Michael Crowther
Chief Commercial & Strategy Officer
Mr. Matthew E. Ros
Chief Operating Officer
Mr. Daniel Calkins
Chief Financial Officer
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer
Mr. Nate Sanburn
Chief Business Officer
Mr. Daniel W. Paterson
President, Chief Executive Officer & Director
Dr. Michelle Detwiler M.D., Ph.D.
Co-Founder